|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results||deaths E||clinical improvement E||death or ventilation E|
COVID-19 severe or critically meta-analysis
|COV-BARRIER (critically ill), 2022|
|RCT||baricitinib||placebo||COVID-19 severe or critically||low||51/50||suggested|
|1 study excluded by filtering options (0 RCT / 1 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).